Chuck Grassley actually said...

Our investigation found that the PBM scheme encourages drug makers to spike the drug's list price in order to offer a greater rebate.

Today, three PBMs control 80 percent of the market.

It requires the FTC to study pharmaceutical intermediaries and issue a report and recommendations to Congress within one year.

Any true attempt at understanding the factors driving costs must include a look at the broader supply chain.